Key clinical point: Significant improvement in work productivity was observed in a real-world cohort of patients with psoriatic arthritis (PsA) treated with a tumor necrosis factor inhibitor (anti-TNF).
Major finding: At the final follow-up visit, the overall activity impairment decreased from 55.0 ± 21.5 to 16.3 ± 18.2 ( P < .001). Moreover, absenteeism, mean presenteeism, and work productivity loss showed significant improvement upon treatment at the 9-month follow-up visit (all P < .001).
Study details: Findings are from a noninterventional, prospective, and observational cohort study including 120 patients with PsA who were receiving anti-TNF treatment.
Disclosures: This study was supported by AbbVie. Some of the authors declared receiving speaker’s fees, consulting fees, or research grants from various sources including AbbVie.
Source: Karadag O et al. Clin Rheumatol. 2021 Sep 3. doi: 10.1007/s10067-021-05893-3 .